[Temporary Announcement] Kangkel: Announcement of Resolutions of the Third Extraordinary Shareholders Meeting in 2026
Announcement number: 2026-037
Securities code: 874210 Securities abbreviation: Kangker Sponsoring broker: China International Finance Securities
Announcement of Resolutions of the Third Extraordinary Shareholders Meeting of Chongqing Kangkel Pharmaceutical Co., Ltd. in 2026
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Meeting convening and attendance
(1) Meeting status
Meeting time: September 24, 2026
Meeting method: √On-site meeting □Electronic communication meeting
Company Conference Room, No. 101, Jinyu Avenue, Economic Development Park, Northern New District, Chongqing
- Meeting voting method:
√On-site voting □Electronic communication voting
□Online voting □Other ways to vote
Meeting convener: Board of Directors
Meeting host: Chairman Chen Yongfang
Explanation on the legality and compliance of the convening situation:
The convening, holding and resolution review procedures of this shareholders' meeting are in compliance with the provisions of the Company Law and other laws, regulations, normative documents and the Articles of Association, and the resolutions made are legal and valid.
(2) Meeting attendance
A total of 5 shareholders attended and authorized to attend this shareholders' meeting, holding a total of 74,491,524 shares with voting rights, accounting for 99.9997% of the company's total voting shares.
(3) Attendance of the company’s directors, supervisors and senior managers at the shareholders’ meeting
- The company has 5 current directors and 5 non-voting directors;
Announcement number: 2026-037
The company has 3 serving supervisors and 3 people attending;
The secretary of the company’s board of directors attends the meeting;
Other senior managers of the company attended the meeting.
2. Proposal review status
(1) Consideration and approval of the "Proposal on the Reelection of the Board of Directors and the Election of Directors of the Third Board of Directors"
- Contents of the motion:
In view that the term of the company's second board of directors expires on September 26, 2026, in accordance with the relevant provisions of the "Company Law" and other laws, regulations and normative documents and the "Articles of Association", and after the qualification review of the nomination committee of the board of directors, Ms. Chen Yongfang, Ms. Yang Xufeng, Mr. Tao Qingming, Mr. He Wei and Mr. Liu Qiang are now nominated as directors of the company's third board of directors, with a term of three years from the date of election by the company's shareholders' meeting.
- Proposal voting results:
The number of common shares agreed was 74,491,524, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstention shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Avoid voting situations
This motion does not involve avoidance of voting.
(2) Consideration and approval of the "Proposal on the Reelection of the Supervisory Board and the Election of Non-Employee Representative Supervisors of the Third Supervisory Board" 1. Contents of the proposal:
In view that the term of the company's second board of supervisors expires on September 26, 2026, in accordance with the relevant provisions of the Company Law, other laws, regulations and normative documents and the Articles of Association, Mr. Fu Qiang and Mr. Liu Kui are now nominated as non-employee representative supervisors of the company's third board of supervisors, with a term of three years from the date of election and approval by the company's shareholders' meeting. Mr. Fu Qiang and Mr. Liu Kui are not persons subject to breach of trust and are not prohibited from serving as supervisors as required by laws, regulations and regulatory authorities.
- Proposal voting results:
The number of common shares agreed was 74,491,542, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstention shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
Announcement number: 2026-037
- Avoid voting situations
This motion does not involve avoidance of voting.
3. Effectiveness of the proposals for changes in directors, supervisors and senior managers reviewed at this meeting
Job title
Name Changes Effective Date Meeting Name Effectiveness
weigh
Chen Yongfang Director took office 2026-09-24 Approved at the third interim review in 2026
shareholders meeting
Yang Xufeng Director took office on 2026-09-24 and was approved at the third interim review in 2026
shareholders meeting
Tao Qingming Director took office 2026-09-24 Approved at the third interim review in 2026
shareholders meeting
He Wei Director took office 2026-09-24 Approved at the third interim review in 2026
shareholders meeting
Liu Qiang Director took office 2026-09-24 Approved at the third interim review in 2026
shareholders meeting
Fu Qiang Supervisor took office on 2026-09-24 and passed the third interim review in 2026
shareholders meeting
Liu Kui Supervisor took office on 2026-09-24 and was approved at the third interim review in 2026
shareholders meeting
4. Documents for reference
"Resolution of the Third Extraordinary Shareholders Meeting of Chongqing Kangker Pharmaceutical Co., Ltd. in 2026"
Chongqing Kangker Pharmaceutical Co., Ltd.
board of directors
Announcement Number: 2026-037 September 29, 2026